Cyanovirin-N binds to select SARS-CoV-2 spike oligosaccharides outside of the receptor binding domain and blocks infection by SARS-CoV-2

Significance The antiviral lectin cyanovirin-N (CV-N) is shown to have potent activity against the syndromecoronavirus 2 (SARS-CoV-2) virus. CV-N showed improved binding and potency against more recent SARS-CoV-2 variants of concern and is shown to be able to reduce the severity of SARS-CoV-2 infections in test animals. The mechanism of action for CV-N is distinct from that of currently used anti-COVID therapeutics or from common vaccine targets on the receptor binding domain. CV-N is a potential broad-spectrum agent against infection from SARS-CoV-2.

[1]  S. Gharbia,et al.  Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant , 2022, The New England journal of medicine.

[2]  Rommie E. Amaro,et al.  The roles of glycans in the SARS-CoV-2 spike protein , 2022, Biophysical Journal.

[3]  R. Paredes,et al.  Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection , 2022, Cell Reports Medicine.

[4]  H. Jäck,et al.  The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic , 2021, Cell.

[5]  Zhonglei Wang,et al.  In the age of Omicron variant: Paxlovid raises new hopes of COVID‐19 recovery , 2021, Journal of medical virology.

[6]  S. Madhi,et al.  Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses , 2021, bioRxiv.

[7]  Junhua Pan,et al.  Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain , 2021, Science.

[8]  S. Karim,et al.  Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic , 2021, The Lancet.

[9]  J. Cipollo,et al.  Site-Specific Glycosylation Patterns of the SARS-CoV-2 Spike Protein Derived From Recombinant Protein and Viral WA1 and D614G Strains , 2021, Frontiers in Chemistry.

[10]  Catherine Z. Chen,et al.  A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry , 2021, bioRxiv.

[11]  Dongqing Wei,et al.  Discovery of a Natural Product with Potent Efficacy Against SARS-CoV-2 by Drug Screening , 2021, Interdisciplinary sciences, computational life sciences.

[12]  Jordan J. Clark,et al.  A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19 , 2021, Nature Communications.

[13]  M. Suchard,et al.  Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil , 2021, Science.

[14]  Rommie E. Amaro,et al.  A glycan gate controls opening of the SARS-CoV-2 spike protein , 2021, bioRxiv.

[15]  R. Paredes,et al.  Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen , 2020, Frontiers in Pharmacology.

[16]  A. Pollard,et al.  What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2 , 2020, The Lancet Infectious Diseases.

[17]  Fiona Russell,et al.  Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines , 2020, Frontiers in Immunology.

[18]  S. Munro,et al.  Furin cleavage of SARS-CoV-2 Spike promotes but is not essential for infection and cell-cell fusion , 2020, bioRxiv.

[19]  M. Gorrell.  Faculty Opinions recommendation of Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[20]  Rommie E. Amaro,et al.  Beyond Shielding: The Roles of Glycans in SARS-CoV-2 Spike Protein , 2020, bioRxiv.

[21]  Daniel Wrapp,et al.  Site-specific glycan analysis of the SARS-CoV-2 spike , 2020, Science.

[22]  Xiaofang Pei,et al.  The Coronavirus Disease 2019 (COVID-19) Pandemic. , 2020, The Tohoku journal of experimental medicine.

[23]  Zhicong Yang,et al.  The SARS-CoV-2 outbreak: What we know , 2020, International Journal of Infectious Diseases.

[24]  A. Walls,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[25]  Naveen Vankadari,et al.  Emerging COVID-19 coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26 , 2020, Emerging microbes & infections.

[26]  Yun Lei,et al.  Preparation of a monoPEGylated derivative of cyanovirin-N and its virucidal effect on acyclovir-resistant strains of herpes simplex virus type 1 , 2019, Archives of Virology.

[27]  J. C. Kouokam,et al.  Lectins as Promising Therapeutics for the Prevention and Treatment of HIV and Other Potential Coinfections , 2018, BioMed research international.

[28]  J. Dubuisson,et al.  Middle East respiratory syndrome coronavirus infection is inhibited by griffithsin , 2016, Antiviral Research.

[29]  P. Christou,et al.  Cyanovirin-N produced in rice endosperm offers effective pre-exposure prophylaxis against HIV-1BaL infection in vitro , 2016, Plant Cell Reports.

[30]  P. Christou,et al.  Rice endosperm is cost‐effective for the production of recombinant griffithsin with potent activity against HIV , 2016, Plant biotechnology journal.

[31]  Guoying Yu,et al.  Preparation of monoPEGylated Cyanovirin-N's derivative and its anti-influenza A virus bioactivity in vitro and in vivo. , 2015, Journal of biochemistry.

[32]  Valentine Wanga,et al.  Improving the large scale purification of the HIV microbicide, griffithsin , 2015, BMC Biotechnology.

[33]  K. Ramessar,et al.  Engineering soya bean seeds as a scalable platform to produce cyanovirin‐N, a non‐ARV microbicide against HIV , 2015, Plant biotechnology journal.

[34]  Zhiping Weng,et al.  ZDOCK server: interactive docking prediction of protein-protein complexes and symmetric multimers , 2014, Bioinform..

[35]  Albert Sickmann,et al.  N-glycoproteomics: mass spectrometry-based glycosylation site annotation , 2012, Biological chemistry.

[36]  D. Meyerholz,et al.  Broad-Spectrum In Vitro Activity and In Vivo Efficacy of the Antiviral Protein Griffithsin against Emerging Viruses of the Family Coronaviridae , 2009, Journal of Virology.

[37]  David C. Montefiori,et al.  Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component , 2009, Proceedings of the National Academy of Sciences.

[38]  C. Pannecouque,et al.  Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle , 2007, Antiviral Research.

[39]  Jean Dubuisson,et al.  Cyanovirin-N Inhibits Hepatitis C Virus Entry by Binding to Envelope Protein Glycans* , 2006, Journal of Biological Chemistry.

[40]  S. Brooks,et al.  Protein glycosylation in diverse cell systems: implications for modification and analysis of recombinant proteins , 2006, Expert review of proteomics.

[41]  J. Ma,et al.  Transgenic plant production of Cyanovirin‐N, an HIV microbicide , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[42]  M. Betenbaugh,et al.  Comparing N-glycan processing in mammalian cell lines to native and engineered lepidopteran insect cell lines , 2004, Glycoconjugate Journal.

[43]  K. Gustafson,et al.  Potent Anti-Influenza Activity of Cyanovirin-N and Interactions with Viral Hemagglutinin , 2003, Antimicrobial Agents and Chemotherapy.

[44]  Mike Bray,et al.  Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus. , 2003, Antiviral research.

[45]  L. Pannell,et al.  A potent novel anti-HIV protein from the cultured cyanobacterium Scytonema varium. , 2003, Biochemistry.

[46]  A. Gronenborn,et al.  Multisite and multivalent binding between cyanovirin-N and branched oligomannosides: calorimetric and NMR characterization. , 2002, Chemistry & biology.

[47]  Alexander Wlodawer,et al.  Structures of the Complexes of a Potent Anti-HIV Protein Cyanovirin-N and High Mannose Oligosaccharides* , 2002, The Journal of Biological Chemistry.

[48]  M. Boyd,et al.  Cyanovirin-N defines a new class of antiviral agent targeting N-linked, high-mannose glycans in an oligosaccharide-specific manner. , 2001, Molecular pharmacology.

[49]  M. Boyd,et al.  Selective interactions of the human immunodeficiency virus-inactivating protein cyanovirin-N with high-mannose oligosaccharides on gp120 and other glycoproteins. , 2001, The Journal of pharmacology and experimental therapeutics.

[50]  K. Nagashima,et al.  The HIV-inactivating protein, cyanovirin-N, does not block gp120-mediated virus-to-cell binding. , 1998, Biochemical and biophysical research communications.

[51]  L K Pannell,et al.  Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development , 1997, Antimicrobial agents and chemotherapy.

[52]  M. Sherman,et al.  A Preliminary Report , 1953 .

[53]  HENRY E. ARMSTRONG,et al.  What We Know , 1926, Nature.